Navigation Links
Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
Date:8/31/2007

Gov. Kaine's independent panel urges less restrictive commitment standard

ARLINGTON, Va., Aug. 31 /PRNewswire-USNewswire/ -- What happened to keep Seung Hui Cho from getting needed treatment and at what point could the Virginia Tech massacre have been prevented? The state-appointed panel charged with answering those questions released its report today, stating in part that "The Virginia standard for involuntary commitment is one of the most restrictive in the nation and is not uniformly applied."

The report details the many lost opportunities to help Cho and makes recommendations to improve Virginia's restrictive mental health treatment law.

The panel recommended that the involuntary treatment criteria be improved to "allow involuntary treatment in a broader range of cases involving severe mental illness." The current standard for involuntary commitment in Virginia for someone with a severe mental illness requires a person to be an "imminent danger to self or others" before he or she can be court-ordered to treatment. This makes it difficult, if not impossible, to treat someone before they have harmed his or her self or someone else, or threatened to do so. About half of states have more humane standards that focus on the person's deteriorating condition and "need for treatment," rather than requiring them to deteriorate to "dangerousness."

The panel recommended that "reports of prior psychiatric history" be presented at the commitment hearing. Current Virginia law instructs magistrates to rely solely on what is happening currently with a person with untreated severe mental illness, ignoring what happened in the past. That means past episodes of violence, psychiatric history, and past treatment are not considered. As is clear from the extensive report on Cho, past history is not only relevant, but oftentimes critical.

"Gov. Kaine and the independent panel should be commended for not only identifying many of the flaws in the
'/>"/>

SOURCE Treatment Advocacy Center
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Once a Lawn Mower, a Self-made Billionaire Makes a Lasting Gift to Virginia Tech
2. West Virginia Organizes a Program to Fight Obesity
3. Indians Add to Rich Diversity of Virginia Tech
4. Virginia Tech. Shooter -Human Rights or Innocent Lives
5. Virginia Tech Shooters Mental Health Records No More Secret
6. Fire Ants are Emerging Nuisance for Virginians
7. Australian Devises Online Game Based on Virginia Tech Shootout
8. Pain Doctor in Virginia Sentenced to Five Years Imprisonment
9. Five Killed by Methane Gas on Virginia Farm
10. FDA may speed review of new drugs
11. Scientists review SARS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 Acute coronary syndrome (ACS) ... healthcare costs, frequent recurrences and hospitalizations, and high ... ACS incidence increases with age and will be ... population increases around the world. ACS is classified ... heart muscle damage inferred from a person’s symptoms, ...
(Date:7/14/2014)... 14, 2014 Georgia State University ... groups under the fifth round of its Second ... of research and academic performance. , The ... of top-notch faculty members to the university, with ... in areas of national significance. , “With the ...
(Date:7/14/2014)... through the bloodstream, homing in on a sheath ... and metastasize to other organs, scientists at The ... in Cancer Cell . , "This completely ... provides new potential avenues to predict and prevent ... M.D., professor of Gynecologic Oncology and Reproductive Medicine ...
(Date:7/14/2014)... look back on 40 years of the Glasgow Coma Scale ... and clinical practice, in a new Personal View published in ... Personal View is published on the 40th anniversary of the ... Since this seminal publication, the Glasgow Coma Scale has provided ... level, the clinical hallmark of acute brain injury. The scale ...
(Date:7/14/2014)... D.C., July 14, 2014 A recent study published ... of the American Academy of Child and Adolescent Psychiatry ... the age of onset criterion for diagnosis of attention-deficit/hyperactivity ... for ADHD, previously set at 7 in DSM-IV, has ... of onset is now set at 12, rather than ...
Breaking Medicine News(10 mins):Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 2Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 3Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 4Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 3Health News:MD Anderson researchers discover new route for ovarian cancer spread 2Health News:MD Anderson researchers discover new route for ovarian cancer spread 3
... a novel study on condom use with help from ,scientists, ... the significance of condom use in curtailing spread of AIDS. ... study on a request from Pope Benedict XVI. The cardinal ... abstinence from sex in the fight against AIDS. ...
... has been approved by the Food and Drug Administration ... cyanide poisoning//. The kit contains the drug hydroxocobalamin, intravenous ... enables emergency treatment for known or suspected cyanide poisoning. ... to emergencies including possible attacks by terrorists is enhanced. ...
... people seeking medical help because of illnesses related to alcohol ... few years//. ,Current official statistics show that ... treated for accidents and emergencies caused due to drunkenness ... for the same also have doubled, reported NHS since 1997, ...
... given rise not only to high expectations of treatment ... the German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) issued its ... developed enormously. ,The second memorandum, which ... on Genetic Research, makes it clear that gene therapy ...
... research study finds that 95 percent of Americans have pre ... new as American men //and women as far back as ... disappointed that spending hundreds of millions of dollars advising young ... being wasted. One official disagreed and opined that even if ...
... ingredient of psychedelic mushrooms, also called magic mushrooms ... disorder (OCD), according to a study// by University ... substances like psilocybin, psilocin, or muscimol. ,The ... 1970, according to AP reports. ,The intent ...
Cached Medicine News:Health News:Gene Therapy for Hereditary Immunodeficiency Diseases 2
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... 11, 2010 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... Tuesday, November 16 at the American Heart Association (AHA) ... and chief executive officer of Thoratec, will be discussing ...
... 2010 Ardea Biosciences, Inc. (Nasdaq: RDEA ... trials of BAY 86-9766 (formerly known as RDEA119) will ... and Treatment of Cancer (EORTC) – National Cancer Institute ... on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. ...
Cached Medicine Technology:Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 3Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4